Heart Attack

ŌURA Announces Two New Heart Health Features, Moving Deeper into Preventative HealthŌURA Announces Two New Heart Health Features, Moving Deeper into Preventative Health

ŌURA Announces Two New Heart Health Features, Moving Deeper into Preventative Health

New Cardiovascular Age and Cardio Capacity capabilities further establish ŌURA as a personal health companion for improving healthspan and longevitySAN…

1 year ago
Biotricity Expands Market Reach to Pulmonary and Neurology Fields Through Latest Partnerships with Two Leading Home-Based Diagnostic CompaniesBiotricity Expands Market Reach to Pulmonary and Neurology Fields Through Latest Partnerships with Two Leading Home-Based Diagnostic Companies

Biotricity Expands Market Reach to Pulmonary and Neurology Fields Through Latest Partnerships with Two Leading Home-Based Diagnostic Companies

REDWOOD CITY, CA / ACCESSWIRE / April 30, 2024 / Biotricity Inc. (NASDAQ:BTCY), a groundbreaking Technology-as-a-Service (TaaS) company committed to…

1 year ago
Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued PatentsOrchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents

Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents

Patent estate covering atrioventricular interval modulation (“AVIM”) therapy includes 37 issued U.S. patents and 73 patents outside the U.S. that…

1 year ago
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024

Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024

NEW HOPE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”),…

1 year ago
JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertensionJERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension

JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension

Ad hoc announcement pursuant to Art. 53 LR Idorsia receives a positive opinion from the Committee for Medicinal Products for…

1 year ago
New Study Shows 94% Reduction in COVID-19 Cases in a Residential Healthcare Facility With ActivePure TechnologyNew Study Shows 94% Reduction in COVID-19 Cases in a Residential Healthcare Facility With ActivePure Technology

New Study Shows 94% Reduction in COVID-19 Cases in a Residential Healthcare Facility With ActivePure Technology

Technology offers timely and cost-efficient infection prevention solution for long-term care amidst industry-wide labor shortagesDALLAS, TX / ACCESSWIRE / April…

1 year ago
Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in MichiganExponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan

Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan

Exponential Health, an innovative concierge medicine practice in Michigan, adopts Cardio Diagnostics' AI-driven epigenetic-genetic tests, marking a new era in…

1 year ago
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of ActionDUBLIN, Ireland and BRIDGEWATER, N.J., April 08, 2024 (GLOBE NEWSWIRE) --…

1 year ago
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world settingNew Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal…

1 year ago